Projekt
XATOC – Xarelto + Acetylsalicylic Acid
Abgeschlossen - Rekrutierung – beendet · 2020 bis 2023
Rickli Hans, Fink Karin
Art
Reichweite
Bereiche
Status
Start
Ende
Finanzierungsart
Studiendesign
Schlagwörter (Tags)
Kurzbeschreibung/Zielsetzung
Treatment patterns and Outcomes across the disease Continuum in
patients with CAD and/or PAD
The study aims to collect real-world data on treatment
patterns and decision points for treatment in patients with
coronary artery disease (CAD) or symptomatic peripheral
artery disease (PAD) treated with rivaroxaban 2.5 mg [twice
a day (BID)] plus low-dose ASA (75-100 mg) [once a day
(OD)] for the prevention of atherothrombotic events in adult
patients at high risk of ischemic events, and to describe the
outcomes under this combination across the broad range of
patient risk profiles encountered in routine clinical practice